GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis

$591,007
Efstathios Karathanasis · Case Western Reserve University · R01 · FY2020 · CA

Pathology Core

$590,984
Geoffrey I Shapiro · Dana-Farber Cancer Inst · P01 · FY2025 · CA

(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis

$590,958
Noula Dattu Shembade · University Of Miami School Of Medicine · R01 · FY2022 · CA

preclinical optimization of BCMA directed T cell therapy

$590,784
Marta Chesi · Mayo Clinic Arizona · R01 · FY2024 · CA

Post-Initiation control of transcription in inflammatory macrophages

$590,756
Inez Rogatsky · Hospital For Special Surgery · R01 · FY2023 · AI

Post-Initiation control of transcription in inflammatory macrophages

$590,756
Inez Rogatsky · Hospital For Special Surgery · R01 · FY2022 · AI

Post-Initiation control of transcription in inflammatory macrophages

$590,756
Inez Rogatsky · Hospital For Special Surgery · R01 · FY2024 · AI

The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers

$590,346
Cristian T Badea · Duke University · U24 · FY2019 · CA

Administrative Core

$590,179
Jun Yan · University Of Louisville · P20 · FY2024 · GM

Reprogramming the pancreatic tumor microenvironment with immunotherapy

$590,123
Lei Zheng · Johns Hopkins University · R01 · FY2019 · CA

Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer

$590,100
Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2023 · CA

Optimization of an active mutant KRAS peptide vaccine in colorectal cancer

$589,838
Nilofer S. Azad · Johns Hopkins University · R01 · FY2025 · CA

Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer

$589,762
Joseph A Califano · University Of California, San Diego · R01 · FY2024 · CA

Rational approaches to melanoma therapy

$589,729
Meenhard Herlyn · Wistar Institute · U54 · FY2022 · CA

Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC

$589,164
Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Finding the optimal balance of immunotherapy efficacy and toxicity.

$589,033
David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2020 · AI

Credentialing Mouse Models for Immune System Therapy Research

$588,966
Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2015 · CA

Glycosylation and Immune Evasion in Urologic Tumors

$588,870
Sharon Pitteri · Stanford University · U01 · FY2022 · CA

Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion

$588,394
Ioannis Vlachos · Beth Israel Deaconess Medical Center · R01 · FY2025 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

$588,065
Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Molecular Digital CytoImaging for Leukemia Drug Screening

$587,933
Tothu Q Vu · Oregon Health & Science University · R01 · FY2020 · CA

Molecular Targeting of Diffuse Large B-cell Lymphoma

$587,846
Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2011 · CA

Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients

$587,495
Khandan Keyomarsi · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer

$587,394
Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2024 · CA